OPEN ACCESS Freely available online

Journal of Tumor Research

Short communication

Wilms' Tumor of the Kidneys: Etiology and Post-Operative Care

Nicolas Saltzman*

Department of Nephrology, University of Colorado School of Medicine, Aurora, USA

DESCRIPTION

Nephroblastoma, also known as Wilms' tumor or Wilms tumor, is a type of kidney cancer that most frequently manifests as a renal tumor in young individuals. It is uncommon in adults. The German surgeon Max Wilms (1867-1918), who first reported it, is remembered by the name of the phenomenon. It is the fourth most frequent form of pediatric cancer overall and the most prevalent form of pediatric renal, abdominal and other cancers combined [1].

Etiology

There are numerous causes of Wilms' tumor, which can be broadly divided into syndromic and non-syndromic groups. Wilms' tumor has syndromic origins that result from changes to genes like the Wilms' Tumor 1 (WT1) or Wilms Tumor 2 (WT2), and the tumor exhibits a variety of additional signs and symptoms. There is no correlation between non-syndromic Wilms tumor and additional symptoms or diseases. Nephrogenic rests, which are tissue pieces in or around the kidney that grow before birth and turn malignant after birth, are the cause of many, but not all, cases of Wilms' tumor. Nephrogenic rests are particularly important in cases of bilateral Wilms tumor and cases of Wilms tumor resulting from specific genetic abnormalities like Denys-Drash syndrome. Nephroblastomas often only affect one side of the body; less than 5% of cases include both sides [2,3].

Histopathology

Wilms tumor is classified into favorable and unfavorable histologies.

90 percent of Wilms tumors will have favorable histology, which often has a better prognosis. An arrangement of blastema, epithelial and stromal tissues in a triphasic pattern is one of the traditional histological characteristics of a favorable Wilms tumor. The most undifferentiated and conceivably most cancerous component is the blastema. Wide variations in differentiation of the epithelial component indicating nephrogenesis at various developmental stages, can be seen from an early tubular formation with rudimentary epithelial rosette-like structures to developing tubules or glomeruli-like structures. Undifferentiated mesenchymal cells that are tightly packed together or loose cellular myxoid regions could make up the stromal component.

Wilms tumors with unfavorable histology will have much greater levels of anaplasia, which is histologically described as hyperchromatic, pleomorphic nuclei that are three times larger than surrounding cells and show aberrant mitotic figures. Poor treatment outcomes are linked to anaplasia and are linked to a somewhat worse prognosis and survival [4,5].

Staging

Stage I tumors have no vascular invasion and are entirely confined within the kidney, with no fractures or spills outside the renal capsule. For 40% to 45% of all Wilms tumors, this stage is present.

Stage II would be a tumor that has extended somewhat outside the kidney, like into the nearby fatty tissue. Surgery would typically remove the entire tumor and local lymph nodes would be clear. At this stage, 20% of Wilms tumors are present.

About 20% to 25% of Wilms tumors are classified as Stage III, which denotes a tumor that could not be entirely removed surgically, such as the following:

- The local lymph nodes have been affected by the cancer, but not more distant nodes, such as those in the chest.
- The cancer could not be entirely eliminated surgically since it had spread to neighboring important structures.
- During surgery, cancer cells unintentionally "spilled" into the abdominal cavity.

Stage IV tumors are those that have reached distant organs including the lungs, liver, brain or bones through the vascular system, as well as distant lymph nodes. About 10% of all Wilms tumors are this.

When both kidneys are affected by tumor at the time of initial diagnosis, the condition is referred to as Stage V. In this stage, 5% of Wilms tumors are present. Additionally, each renal unit needs to be staged individually [6,7].

Correspondence to: Dr. Nicolas Saltzman, Department of Nephrology, University of Colorado School of Medicine, Aurora, USA, E-mail: niman@coltz.edu

Received: 25-May-2023, Manuscript No. JTDR-23-24391; **Editor assigned:** 29-May-2023, Pre QC No. JTDR-23-24391 (PQ); **Reviewed:** 12-Jun-2023, QC No. JTDR-23-24391; **Revised:** 19-Jun-2023, Manuscript No. JTDR-23-24391 (R); **Published:** 26-Jun-2023, DOI: 10.35248/2684-1258.23.09.194

Citation: Saltzman N (2023) Wilms' Tumor of the Kidneys: Etiology and Post-Operative Care. J Tumor Res. 9:194

Postoperative and rehabilitation care

Patients must have the following monitored immediately following surgery:

- Urine production, electrolytes, temperature and blood glucose
- Follow-up visits for Wilms tumor may include:

Check for liver/veno-occlusive disease in patients with right-sided tumors who received radiation treatment.

Feel the abdomen for any signs of any local recurrence or a liver tumor. Listen to the lungs for any signs of metastasis.

Feel the thyroid for any growths (if the child had radiation therapy to the chest).

Breast examination in female patients who had radiation therapy to the chest.

Testing is a component of aftercare. These will consist of an annual abdominal ultrasound

The following procedures are performed on patients who have received carboplatin: CT scan, MRI, chest x-ray, liver function testing, renal function blood tests, and early infertility screening and hearing tests [8,9].

- Echocardiograms or electrocardiograms or other cardiac function testing, at least every three years for patients who had doxorubicin (Adriamycin).
- Patients who have had abdominal radiation should begin early screening for colon cancer 10 years after finishing radiotherapy or by age 35, whichever comes later.
- The following is applied after radiotherapy to the chest or lungs:

Thyroid US is advised every three years to check for thyroid nodules and masses.

Thyroid-Stimulating Hormone (TSH) and free Thyroxine (T4) are used to assess thyroid function.

Early osteoporosis necessitates starting bone density testing 10 years earlier than usual.early breast cancer detection in women [10].

CONCLUSION

Wilms' tumor is a cancer of the kidney that typically occurs in children and is highly responsive to treatment, with 90% of children being cured. It is diagnosed through a medical history, physical exam, and imaging tests. An ultrasound scan is used to confirm the presence of an intrarenal mass, and a tissue sample is used to confirm the diagnosis. Treatment is nephrectomy or chemotherapy followed by nephrectomy. Patients with Wilms tumor must have blood pressure, electrolytes, temperature and blood glucose monitored. Tests include abdominal ultrasound, CT scan, MRI, chest x-ray, liver function testing, renal function blood tests, early screening for infertility, hearing tests, cardiac function tests, early screening for colon cancer, Thyroid-Stimulating Hormone (TSH), free Thyroxine (T4), thyroid US, bone density testing and early screening for breast cancer.

REFERENCES

1. Mullen EA, Chi YY, Hibbitts E, Anderson JR, Steacy KJ, Geller JI, et al. Impact of surveillance imaging modality on survival after recurrence in patients with favorable-histology Wilms tumor: a report from the Children's Oncology Group. J Clin Oncol. 2018;36(34): 3396.
2. Fitski M, van de Ven CP, Hulsker CC, Bökkerink GM, van Scheltinga CE, van den Heuvel-Eibrink MM, et al. Patient-specific hydrogel phantoms for the preoperative simulation of nephron-sparing surgery in Wilms' tumor patients: A feasibility study. Annals of 3D Printed Medicine. 2022;8:100077.
3. Heuvel-eibrink MV, Hol JA, Pritchard-Jones K, Tinteren HV, Furtwängler R, Verschuur AC, et al. Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol. Nat Rev Urol. 2017;14(12):743-752.
4. Erginel B, Vural S, Akın M, Karadağ ÇA, Sever N, Yıldız A, et al. Wilms' tumor: a 24-year retrospective study from a single center. Pediatr Hematol Oncol. 2014;31(5):409-414.
5. Guaragna MS, Soardi FC, Assumpcao JG, Zambaldi LD, Cardinalli IA, Yunes JA, et al. The novel WT1 gene mutation p. H377N associated to Denys-Drash syndrome. J Pediatr Hematol Oncol. 2010;32(6):486-488.
6. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell. 1990;60(3): 509-520.
7. Maiti S, Alam R, Amos CI, Huff V. Frequent association of β-catenin and WT1 mutations in Wilms tumors. Cancer Res. 2000;60(22):6288-6292.
8. Hol JA, Jewell R, Chowdhury T, Duncan C, Nakata K, Oue T, et al. Wilms tumour surveillance in at-risk children: Literature review and recommendations from the SIOP-Europe Host Genome Working Group and SIOP Renal Tumour Study Group. Eur J Cancer. 2021;153:51-63.
9. Breslow NE, Norris R, Norkool PA, Kang T, Beckwith JB, Perlman EJ, et al. Characteristics and outcomes of children with the Wilms tumor-Aniridia syndrome: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2003;21(24):4579-4585.
10. Brok J, Treger TD, Gooskens SL, van den Heuvel-Eibrink MM, Pritchard-Jones K. Biology and treatment of renal tumours in childhood. Eur J Cancer. 2016;68:179-195.